Prior Authorization Criteria

AKYNZEO (netupitant/palonosetron) PA Criteria:

INDICATIONS AND USAGE:
Akynzeo capsules is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
Akynzeo capsules are a combination of palonosetron and netupitant: palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.
Akynzeo for injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Akynzeo for injection is a combination of palonosetron and fosnetupitant, a prodrug of netupitant: palonosetron prevents nausea and vomiting during the acute phase and fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.

Diagnosis: ___________________________ ICD-10 code(s) plus description:__________________________

Initial authorization: 6 months:
(Answers to ALL the following should be YES):
• ☐ Yes ☐ No  Age 18 years or older;
AND
• ☐ Yes ☐ No Documented diagnosis of cancer OR antineoplastic history
AND
• ☐ Yes ☐ No is being prescribed for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy
AND
• ☐ Yes ☐ No History of prior use of preferred combination antiemetic therapy
AND
• ☐ Yes ☐ No Concurrent use of dexamethasone per Package Insert labeling

Highly emetogenic chemotherapy*
• Day 1: Akynzeo  1 (one) capsule 1 (one) hour prior to initiation of chemotherapy
  OR
  Akynzeo 1 vial infused over 30 minutes starting 30 minutes before chemotherapy
  AND
  Dexamethasone: Twelve (12) mg – administer 30 minutes prior to chemotherapy
• Day 2 and 4: Dexamethasone eight (8) mg once a day

**Anthracyclines and Cyclophosphamide-Based Chemotherapy and Chemotherapy Not Considered Highly Emetogenic**

• Day 1: Akynzeo One (1) capsule one (1) hour prior to initiation of chemotherapy
  **AND**
  • Dexamethasone: Twelve (12) mg – administer 30 minutes prior to initiation of chemotherapy.

**How Supplied:**

**Akynzeo (300 mg netupitant/0.5 mg palonosetron) capsules**
• One capsule in one blister or pack of four capsules (two capsules per blister strip)

**Akynzeo (235 mg fosnetupitant/0.25 mg palonosetron) for injection:**
• Sterile, white to off-white lyophilized powder in single-dose vial for reconstitution–pack of one vial

**Reauthorization:** 6 months

*Class of emetogenic therapy as defined by FDA label, compendia or NCCN guidelines*

**Limitations of Use**
• Akynzeo for injection has not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy

**Quantity Limits:** 1 capsule per chemotherapy session.